Tag Archives: FCA claims
Sanofi-Aventis Earns $38 Million for Role in Blowing Whistle on Maker of EpiPens
Sanofi-Aventis, a large pharmaceutical company, was awarded $38.7 million for its role in bringing a $465 million False Claims Act case against Mylan. The company settled amid allegations that it knowingly misclassified EpiPen as a generic drug so it could avoid paying back the rebates it owed to Medicaid. The lawsuit was initially filed under […]
